SPRO

0.742010.20%
DJ

Debra Jeske Zack

Chief Medical Officer

Dr. Debra Jeske Zack, M.D., Ph.D. serves as Chief Medical Officer at Spero Therapeutics, Inc. from July 2026. She had been Chief Medical Officer at Exagen Inc. since March 24, 2020 until December 05, 2022. She served as Vice President of Clinical Development at Xencor, Inc. since September 2014. Dr. Zack joined Xencor with more than a decade of experience in drug development. Prior to joining Xencor, Dr. Zack served as Executive Director, medical scientific leader at Novartis Institute for Biological Research where she provided guidance in translational medicine for early project teams in rheumatology and regenerative medicine. Before that, she had a long career at Amgen in various pre-clinical, clinical development and medical affairs roles, including the Executive Director, global development lead for Enbrel and Executive Director, global product area lead for rheumatology and dermatology. She served as the Executive Director in Inflammation Global Development of Amgen. Dr. Zack served as Member of Scientific Advisory Board of Anthera Pharmaceuticals, Inc. since February 2008. Dr. Zack is a board-certified rheumatologist with a Ph.D. in immunology and extensive drug development experience spanning research, clinical development and medical affairs. She was an associate professor treating rheumatology patients for many years at UCLA prior to joining industry. She earned her bachelor's degree in math and chemistry from Texas Christian University. She completed M.D. and Ph.D. from the University of Texas Southwestern in Dallas. She completed her residency and rheumatology fellowship at the UCLA School of Medicine.

Positions